Corrigendum to: HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway (Cancer Biology & Therapy, 16, 4, (511–517), 10.1080/15384047.2015.1017691);HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway

Cancer Biology and Therapy

Volumn 16, Issue 4, 2015, Pages 511-517

  Liu, Weijun ^a   Zhang, Zhenyong ^a   Zhang, Yongxue ^a   Chen, Xinju ^a   Guo, Shikui ^a   Lei, Yi ^a   Xu, Yu ^a   Ji, Chao ^b   Bi, Zhigang ^c   Wang, Kunhua ^a,d  

^a KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Autophagy; Colorectal cancer; HMGB1; MEK ERK pathway; Oxaliplatin

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; SHORT HAIRPIN RNA; HMGB1 PROTEIN, HUMAN; PLATINUM COMPLEX;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; WESTERN BLOTTING; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HCT 116 CELL LINE; HT-29 CELL LINE; PHOSPHORYLATION; TUMOR CELL LINE;

APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HCT116 CELLS; HMGB1 PROTEIN; HT29 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; ORGANOPLATINUM COMPOUNDS; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84930220251     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1079449     Document Type: Erratum

References (29)

1. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28: 1254-61; PMID: 20100961; http://dx. doi. org/10. 1200/JCO. 2009. 24. 6116.
2. Gourdier I, Del Rio M, Crabbe L, Candeil L, Copois V, Ychou M, Auffray C, Martineau P, Mechti N, Pommier Y, et al. Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett 2002; 529: 232-6; PMID: 12372606; http://dx. doi. org/10. 1016/S0014-5793(02)03347-1.
3. Napier MP, Ledermann JA. Novel chemotherapeutic agents in colorectal cancer. Eur J Surg Oncol 2000; 26: 605-10; PMID: 11034814; http://dx. doi. org/10. 1053/ejso. 2000. 0955.
4. Waters J, Cunningham D. The changing face of chemotherapy in colorectal cancer. Br J Cancer 2001; 84: 1-7; PMID: 11139304; http://dx. doi. org/10. 1054/bjoc. 2000. 1552.
5. Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 2009; 101: 1543-52; PMID: 19841331; http://dx. doi. org/10. 1093/jnci/djp328.
6. Adlard JW, Richman SD, Seymour MT, Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 2002; 3: 75-82; PMID: 11902527; http://dx. doi. org/10. 1016/S1470-2045(02)00648-4.
7. Poston GJ, Figueras J, Giuliante F, Nuzzo G, Sobrero AF, Gigot JF, Nordlinger B, Adam R, Gruenberger T, Choti MA, et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 2008; 26: 4828-33; PMID: 18711170; http://dx. doi. org/10. 1200/JCO. 2008. 17. 6453.
8. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30; PMID: 14665611; http://dx. doi. org/10. 1200/JCO. 2004. 09. 046.
9. Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005; 31: 90-105; PMID: 15847979; http://dx. doi. org/10. 1016/j. ctrv. 2004. 12. 006.
10. Wakasugi T, Izumi H, Uchiumi T, Suzuki H, Arao T, Nishio K, Kohno K. ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes. Oncogene 2007; 26: 5194-03; PMID: 17297437; http://dx. doi. org/10. 1038/sj. onc. 1210326.
11. Livesey KM, Tang D, Zeh HJ, Lotze MT. Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs 2009; 10: 1269-79; PMID: 19943199.
12. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 2009; 15: 5308-16; PMID: 19706824; http://dx. doi. org/10. 1158/1078-0432. CCR-07-5023.
13. Liu L, YangM, Kang R, Wang Z, Zhao Y, Yu Y, Xie M, Yin X, Livesey KM, Lotze MT, et al. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 2011; 25: 23-31; PMID: 20927132; http://dx. doi. org/10. 1038/leu. 2010. 225.
14. Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, Benschop R, Sparvero LJ, Amoscato AA, Tracey KJ, et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010; 29: 5299-310; PMID: 20622903; http://dx. doi. org/10. 1038/onc. 2010. 261.
15. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331-42; PMID: 15803152; http://dx. doi. org/10. 1038/nri1594.
16. Livesey KM, Kang R, Vernon P, Buchser W, Loughran P, Watkins SC, Zhang L, Manfredi JJ, Zeh HJ 3rd, Li L, et al. p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res 2012; 72: 1996-2005; PMID: 22345153; http://dx. doi. org/10. 1158/0008-5472. CAN-11-2291.
17. Shaul YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta 2007; 1773: 1213-26; PMID: 17112607; http://dx. doi. org/10. 1016/j. bbamcr. 2006. 10. 005.
18. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N. Colorectal cancer. Lancet 2010; 375: 1030-47; PMID: 20304247; http://dx. doi. org/10. 1016/S0140-6736(10)60353-4.
19. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29; PMID: 24399786; http://dx. doi. org/10. 3322/caac. 21208.
20. Xiu P, Dong X, Xu Z, Zhu H, Liu F, Wei Z, Zhai B, Kanwar JR, Jiang H, Li J, et al. Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma. Cancer Sci 2013; 104: 375-82; PMID: 23279642; http://dx. doi. org/10. 1111/cas. 12088.
21. Ekblad L, Johnsson A. Cetuximab sensitivity associated with oxaliplatin resistance in colorectal cancer. Anticancer Res 2012; 32: 783-6; PMID: 22399593.
22. el-akawi Z, Abu-hadid M, Perez R, Glavy J, Zdanowicz J, Creaven PJ, Pendyala L. Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett 1996; 105: 5-14; PMID: 8689632; http://dx. doi. org/10. 1016/0304-3835(96)04245-0.
23. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 2001; 48: 398-406; PMID: 11761458; http://dx. doi. org/10. 1007/s002800100363.
24. Iwatsuki M, Mimori K, Yokobori T, Tanaka F, Tahara K, Inoue H, Baba H, Mori M. A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer. J SurgOncol 2009; 100: 261-6; PMID: 19330779; http://dx. doi. org/10. 1002/jso. 21275.
25. Vie N, Copois V, Bascoul-Mollevi C, Denis V, Bec N, Robert B, Fraslon C, Conseiller E, Molina F, Larroque C, et al. Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. Mol Cancer 2008; 7: 14; PMID: 18221502; http://dx. doi. org/10. 1186/1476-4598-7-14.
26. Ji C, Yang YL, Yang Z, Tu Y, Cheng L, Chen B, Xia JP, Sun WL, Su ZL, He L, et al. Perifosine sensitizes UVBinduced apoptosis in skin cells: new implication of skin cancer prevention? Cell Signal 2012; 24: 1781-9; PMID: 22584119; http://dx. doi. org/10. 1016/j. cellsig. 2012. 05. 003.
27. Ji C, Yang B, Yang Z, Tu Y, Yang YL, He L, Bi ZG. Ultra-violet B (UVB)-induced skin cell death occurs through a cyclophilin D intrinsic signaling pathway. Biochem Biophys Res Commun 2012; 425: 825-9; PMID: 22892127; http://dx. doi. org/10. 1016/j. bbrc. 2012. 07. 160.
28. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R, Nakamura Y. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 2004; 6: 731-40; PMID: 15235609; http://dx. doi. org/10. 1038/ncb1151.
29. Liu F, Zhang Y, Peng Z, Gao H, Xu L, Chen M. High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J Transl Med 2012; 10: 135; PMID: 22747650; http://dx. doi. org/10. 1186/1479-5876-10-135.